Brief report: Effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study.

چکیده اصلی

Individuals with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ). Using a matched cohort design, we evaluated the vaccine effectiveness (VE) of recombinant zoster vaccine (RZV) against HZ among IBD patients aged ≥18 years. Within the Kaiser Permanente Southern California population, individuals who received 2 RZV doses were matched up to 1:3 to RZV-unvaccinated individuals. Individuals were followed from 31 days after the receipt of the 2nd RZV dose until the occurrence of a censoring event. VE was calculated using Cox proportional hazards regression. A self-controlled case series analysis was used to compare the rate of flares in the 30‑day risk window following vaccination with the comparison window among RZV recipients using conditional Poisson regression. The adjusted VE of 2 RZV doses (≥4 weeks apart) against HZ was 65.4% (95% confidence interval [CI]: 40.6%-79.9%) in all IBD patients, 62.7% (17.2%-83.2%) in ulcerative colitis patients, and 70.2% (34.5%-86.4%) in Crohn's disease patients. The VE of 2 doses administered 4 weeks-6 months apart in IBD patients was 62.9% (34.3%-79.1%). The rate ratio for IBD flares was 0.80 (95% CI: 0.58-1.12). In conclusion, RZV provided protection against HZ in IBD patients with no increased risk of IBD flares observed.

متن کامل اصلی